Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Conditions:   Acute Myeloid Leukemia;   Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative;   Chronic Eosinophilic Leukemia, Not Otherwise Specified;   Chronic Myelomonocytic Leukemia;   Chronic Neutrophilic Leukemia;   Dysplasia;   Essential Thrombocythemia;   FGFR1 Gene Rearrangement;   M yelodysplastic Syndrome;   Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Myeloid Neoplasm;   Myeloproliferative Neoplasm;   Myeloproliferative Neoplasm, Unclassifiable;   Overt Prima ry Myelofibrosis;   PDGFRA Gene Rearrangement;   PDGFRB Gene Rearrangement;   Polycythemia Vera;   Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase;   Prefibrotic/Early Primary Myelofibrosis Interventions:   Drug: Azacitidine;   Drug: Pevonedistat;   Drug: Venetoclax Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials